Strengthening the Direct Sales and Service System for Business Expansion in Italy
One document
more
Stories about Krankheit
Biomay Announces its Successful Support of Approval of First CRISPR/Cas9-based Therapy
morePress release: STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara - Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within ...
One documentmoreAcousia Therapeutics attracts new investor on its path to make hearing loss a treatable disease
Tübingen (ots) - - German pioneer biotech accelerates hearing loss solution development with fresh capital boost Acousia Therapeutics GmbH, a clinical-stage biotech company developing drug candidates against acute and chronic forms of hearing loss, proudly announces Esperante Ventures as the latest addition to its esteemed group of investors. The infusion of fresh ...
moreCells of the Future: A Key To Reprogramming Cell Identities
moreNew Source of Stem Cells in Injury-Affected Brains of Patients
more
LTS Lohmann Therapie-Systeme AG
LTS receives grant of $1.2 Million to support the development of thermostable mRNA formulations for Microneedle Array Patches
moreTakeda Pharma Vertrieb GmbH & Co. KG
The European Commission Approves Label Update for TAKHZYRO® (lanadelumab), Expanding Its Use to a Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (HAE)
Zurich (ots/PRNewswire) - - TAKHZYRO® is the First Routine Prevention Treatment of HAE Approved in the EU for Patients Under the Age of Six. - The therapeutical indication for TAKHZYRO® has been extended to patients aged 2 years and older.1 - Offers a New Preventative Treatment Option for young HAE patients with ...
moreBehaVR and Fern Health Merge To Form RealizedCare, Launch Digital Care Management Platform to Unlock the Value of Digital Therapeutics
NASHVILLE, Tenn., Aachen, Germany (ots) - The merger will accelerate a new digitally-powered care management solution for chronic pain and beyond; Pharmaceutical company Grünenthal becomes the largest investor in the combined enterprise BehaVR, a pioneering force in digital therapeutics (DTx) experiences, and Fern ...
moreBehaVR and Fern Health Merge To Form RealizedCare, Launch Digital Care Management Platform to Unlock the Value of Digital Therapeutics
NASHVILLE, Tenn., Aachen, Germany (ots) - The merger will accelerate a new digitally-powered care management solution for chronic pain and beyond; Pharmaceutical company Grünenthal becomes the largest investor in the combined enterprise BehaVR, a pioneering force in digital therapeutics (DTx) experiences, and Fern ...
moreTen benefits of a daily intake of citrus fruits during winter season
moreUnderstanding the Role of GIP in Managing Diabetes and Obesity
The increasing amount of patients with obesity and type 2 diabetes benefit greatly from the recently developed GIPR:GLP-1R co-agonists. These novel compounds lead to substantial weight loss, offering a revolutionary approach to patients worldwide. Although the hormone glucose-dependent insulinotropic polypeptide (GIP) was already shown by Helmholtz Munich scientists to decrease body weight via the brain GIP receptor, the ...
more
- 2
PIONEER+ becomes Big Data Platform for Prostate Cancer of the EAU's UroEvidenceHub
more The easiest fruit celebrates its 'Apple Day'
more- 3
EU Provides 1 Mio. to Researchers to Advance Personalised Oncology
One documentmore canSERV Releases Open Call for Transnational Service Provision
One documentmoreHearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial
Tübingen, Germany (ots/PRNewswire) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic ...
moreHearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial
Tübingen, Germany (ots) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic otoprotectant ...
more
Technische Universität München
Minimizing antibiotics usage: “The key starting point is animal health”
TECHNICAL UNIVERSITY OF MUNICH PRESS RELEASE Interview with Prof. Julia Steinhoff-Wagner on antibiotic resistance “The key starting point is animal health” - New research project at TUM addresses the minimization of antibiotics in poultry farming - Healthy animals are the most important precondition for reducing the administration of antibiotics - Transfer of ...
moreDeepMB: A Deep Learning Framework For High-Quality Optoacoustic Imaging in Real-Time
moreTakeda Pharma Vertrieb GmbH & Co. KG
Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older
Zurich (ots/PRNewswire) - - If Approved, Lanadelumab Will be the First Long-Term Prophylactic Treatment of HAE Available in the EU for Patients Under the Age of Six. - Positive Opinion Based on Pivotal Study SHP643-301, Evaluating the Safety Profile and Pharmacokinetics (PK) of Lanadelumab, in Combination with ...
morePress Release: Exercise and Muscle Regulation: Implications for Diabetes and Obesity
How do our muscles respond at the molecular level to exercise? Researchers at Helmholtz Munich and the German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE) have unraveled the cellular basis and signaling pathways responsible for the p ositive impact of physical activity ...
moreTake a Deep Breath: Early Detection of Vascular Disease in Chronic Lung Disease of Premature Infants
Premature infants often struggle with breathing and require ventilatory support and oxygen therapy. Unfortunately, this might lead to lung damage resulting in lifelong consequences and chronic disease. Dr. Anne Hilgendorff’s team from Helmholtz Munich and the LMU University Hospital developed a non-invasive ...
more- 2
Press release : People with Parkinson’s experience variations in effects of oral medicines, but lack advice, international survey reveals
One documentmore
Johnson & Johnson Vision announces launch of ELITA™ Platform to Correct Myopia with New SILK Procedure at the European Society of Cataract and Refractive Surgeons Congress
London (ots/PRNewswire) - Next-generation laser vision correction provides next-day results and recovery1,2 - The next-generation ELITATM Femtosecond Laser to correct myopia with the new SILK procedure** - The latest innovation in extended depth of focus (EDOF) intraocular lenses (IOLs) will be shared with invited ...
moreTechnische Universität München
4D printing for nerve stimulation: Self-folding electrodes stimulate fine nerves
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Self-folding electrodes stimulate fine nerves 4D printing for nerve stimulation - Researchers have produced very fine, flexible electrodes - Upon contact with tissue moisture, the electrodes wrap themselves around thin nerves - Nerve stimulation and recording with the foldable electrodes has already been demonstrated in ...
moreRHEACELL announces “First Patient In”: EB-Haus in Salzburg, Austria starts pivotal study for stem cell therapy for severe forms of Epidermolysis bullosa that is longed for by those affected
more- 5
Press Release - hubergroup India expands its support for rural healthcare
One documentmore The world's first Extended Isolated Stopflow Limb Infusion (EISLI) to treat osteosarcoma results in complete remission
moreInnovation and Start-up Center Biotechnology (IZB) welcomes Invitris
One documentmore
Previous12345678910Next